-transparent.png){kind=logo}
In 10 patients with myasthenia gravis, we studied the relationship between plasma pyridostigmine levels and five measures of neuromuscular function (NMF) following single oral doses of 60 to 120 mg. The NMF measures were percent decrement of the evoked muscle compound potential, maximum force, force-time integral, vital capacity, and outstretched-arm time. The combined mean improvement was most significant 2 hours after pyridostigmine ingestion and coincided with the peak plasma pyridostigmine levels in eight patients. In seven patients, there was a positive correlation between plasma pyridostigmine levels and the mean percent improvement.
Related Publications
H S Milner-Brown, and
M Mellenthin, and
M L Sharma, and
R G Miller
June 1990,
Journal of neurology, neurosurgery, and psychiatry,
H S Milner-Brown, and
M Mellenthin, and
M L Sharma, and
R G Miller
February 1981,
Neurology,
H S Milner-Brown, and
M Mellenthin, and
M L Sharma, and
R G Miller
February 1977,
Clinical pharmacology and therapeutics,
H S Milner-Brown, and
M Mellenthin, and
M L Sharma, and
R G Miller
November 1977,
Neurology,
H S Milner-Brown, and
M Mellenthin, and
M L Sharma, and
R G Miller
June 1985,
Fortschritte der Neurologie-Psychiatrie,
H S Milner-Brown, and
M Mellenthin, and
M L Sharma, and
R G Miller
July 1956,
Canadian Medical Association journal,
H S Milner-Brown, and
M Mellenthin, and
M L Sharma, and
R G Miller
December 1981,
Journal of neurology, neurosurgery, and psychiatry,
H S Milner-Brown, and
M Mellenthin, and
M L Sharma, and
R G Miller
October 1987,
Archives of neurology,
H S Milner-Brown, and
M Mellenthin, and
M L Sharma, and
R G Miller
June 1977,
British journal of clinical pharmacology,
H S Milner-Brown, and
M Mellenthin, and
M L Sharma, and
R G Miller
August 1955,
Revista clinica espanola,
